1	Alpha thalassemia/mental retardation X-linked (ATRX) protein
2	expression in human pituitary neuroendocrine tumours and its
3	reported correlation to prognosis and clinical outcomes: A
4	systematic review.
5	
6	Edward Wang ^{1*} , Fabio Rotondo ² , Michael D. Cusimano ^{1,3}
7	
8	
9	¹ Department of Surgery, Division of Neurosurgery, St. Michael's Hospital; Injury Prevention
10	Research Office, Li Ka Shing Knowledge Institute, Keenan Research Centre; University of Toronto;
11	Toronto, Canada
12	² Department of Laboratory Medicine, Division of Pathology, Unity Health Toronto- St. Michael's
13	Hospital, Toronto, ON, Canada
14	³ Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
15	
16	
17	
18	
19	*Corresponding author
20	Email: <u>ewang242@uwo.ca</u> (EW)

21 Abstract

22 Mutations in Alpha thalassemia/mental retardation X-linked (ATRX) have been implicated 23 in several cancers, including gliomas, sarcomas, neuroendocrine tumors, and other mesenchymal 24 malignancies. ATRX loss contributes to oncogenesis, accelerates tumor growth, and reduces 25 survival by disrupting epigenetic and telomere mechanisms. Additionally, ATRX loss can increase 26 tumor sensitivity to treatment therapies. While research has explored ATRX expression in many 27 cancers, data on its relationship to prognosis in pituitary neuroendocrine tumors (PitNETs) 28 remain inconsistent. This systematic review aims to summarize all available studies on ATRX 29 mutations and expression in PitNETs. A systematic search of PubMed, Scopus, and EMBASE 30 databases was conducted to identify publications between 2014 and 2024 that investigated ATRX 31 mutations or expression in PitNETs, following PRISMA 2020 guidelines. Of 30 identified studies, 32 nine met the inclusion criteria, covering a total of 500 PitNETs. Only 19 tumors (3.6%) showed a 33 loss of ATRX expression. Among these, 58% exhibited corticotropic pathology, while 26% displayed lactotrophic pathology. A small subset of tumors (32%) was classified as pituitary 34 35 carcinomas with aggressive and proliferative characteristics. Additionally, 16% demonstrated the 36 alternative lengthening of telomeres (ALT) phenotype, 53% had concurrent TP53 mutations, and 37 21% had elevated Ki67 indices, indicating a higher proliferative index. Although ATRX mutations 38 are rare in PitNETs, tumors with ATRX loss tend to be more aggressive and exhibit proliferative 39 and transformative properties. Due to the limited number of cases, further studies with larger, 40 prospective cohorts are needed to better understand the role of ATRX loss in PitNET progression 41 and aggressiveness.

42

43 Introduction

44 Alpha thalassemia/mental retardation X-linked (ATRX) is an ATP-dependent chromatin remodelling protein within the switch/sucrose nonfermentable (SWI/SNF) family of chromatin 45 46 remodelling proteins. The ATRX/DAXX complex, which includes death domain-associated protein (DAXX), modulates the deposition of histone H3.3 at guanine-rich heterochromatin regions with 47 highly repetitive elements, including telomeres and pericentromeric regions. [1,2]. ATRX 48 49 preferentially binds to the heterochromatin modification H3K9me3, facilitating histone H3.3 50 deposition and maintaining heterochromatin integrity [3,4]. When ATRX function is disrupted, its 51 silencing action is impaired, leading to aberrant transcription across ATRX/DAXX-regulated 52 regions, including genomic repeats [3]. ATRX mutations have also been linked to the progression 53 of the alternative lengthening of telomeres (ALT) phenotype, a telomerase-independent 54 mechanism for cancer cell immortality [5].

55 Somatic mutations disrupting ATRX function are associated with reduced disease-free 56 survival, genome instability, and increased tumour mutation burden in gliomas, neuroendocrine 57 neoplasms, and mesenchymal tumours [6-8]. Recent investigations have observed poorer 58 prognoses in ATRX-mutated pancreatic neuroendocrine tumours (PanNETs), including shorter 59 disease-free and survival time [6]. Loss of ATRX expression is also linked to increased sensitivity 60 to radiation therapy, chemotherapy, and immunotherapeutic treatments [9]. The fifth edition of 61 the WHO Classification of Tumours of the Central Nervous System (2021) recommends including 62 ATRX status in diagnostic analyses for glioma variants and strongly supports it as a diagnostic marker for PanNET severity and prognoses [6,9]. 63

Pituitary neuroendocrine tumours (PitNETs), traditionally known as pituitary adenomas, 64 65 are common primary intracranial tumours of the adenohypophysis [10]. Like other neuroendocrine tumours, PitNETs are classified based on hormonal secretion. Overproduction 66 67 and secretion of any adenohypophyseal hormones can cause debilitating effects associated with 68 conditions such as acromegaly and Cushing's disease. Although most clinically apparent PitNETs 69 are benign, some exhibit aggressive and invasive growth, leading to mass-effect symptoms from 70 compression of adjacent intracranial structures [11,12]. Metastases are rare and can occur in 71 tumours that appear benign histologically while other tumours that have histological features of 72 aggressiveness can remain isolated to the sellar region. Aggressive and metastatic PitNETs are 73 also resistant to traditional surgical and radiological treatments, with only temozolomide (TMZ) 74 treatment showing moderately effective and often transient pharmacological results in less than 75 half of patients [13,14]. As the use of ATRX as a prognostic marker for other neuroendocrine 76 tumours increases, it is essential to also evaluate whether ATRX can predict the aggressiveness of PitNETs. 77

Currently, published data on the incidence of ATRX expression and its clinical significance in neuroendocrine tumours, particularly PitNETs, is limited. The role of ATRX protein expression in the prognosis of PitNETs remains unknown. In this systematic review, we interpret the existing literature on ATRX expression in PitNETs to better describe its relationship with the clinicopathological characteristics and prognosis of PitNET patients.

83

84 Methods

85 Search strategy

86 This systematic review was conducted following the Preferred Reporting Items for Systematic 87 Reviews and Meta-Analyses (PRISMA) guidelines. The aim was to identify all English published 88 studies on pituitary tumours exhibiting a loss of ATRX expression. The strategy involved searching 89 the PubMed, Embase, and Scopus databases to identify relevant studies published in English from 90 January 1, 2014 to October 1, 2024, using MeSH terms combined with free search terms. A combination of the following keywords was used: ATRX, pituitary, alpha thalassemia X-linked, 91 92 ATRX, PitNET. No other restrictions were imposed, and no attempt was made to obtain 93 unpublished results. All references and supplementary data from all selected articles were also 94 considered. The review was not registered, nor was a review protocol prepared. All data 95 collected and analyzed has been reported in the manuscript.

96 Study selection

97 The selection of published material was conducted based on initial screening of titles or 98 abstracts followed by screening of full-text reviews. Manuscripts were considered eligible if they 99 met the following criteria: (i) the study was published in a peer-reviewed medical journal within 100 the last ten years, (ii) the study was published in English, (iii) the study described human case 101 studies involving pituitary tumours/PitNETs and ATRX, and (iv) the study observed a loss of ATRX 102 expression or mutation in the ATRX gene (Fig 1). Studies were omitted from review based on the 103 following exclusion criteria: (i) studies with publication types other than original research articles, 104 such as review articles, editorials, letters, commentaries, and conference abstracts. Duplicate 105 files were removed following export of database search results to Covidence. Risk of bias

106	assessments were evaluated using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for
107	Studies Reporting Prevalence Data and the JBI Critical Appraisal Checklist for Case Reports [15].
108	Quality assessment was not performed, and therefore no papers were excluded due to poor
109	quality.
110	
111	Fig 1. Identification and selection of studies via databases.
112	
113	Data extraction and quality assessment
114	Data was extracted from selected articles and included the following characteristics:
115	- Study: year of publication, journal of publication, country, type of study
116	- Sample Data: sample size, tumour type studied, mean age of participants at the time of
117	tumour resection, sex, evaluation strategies,
118	- Study Results and Analysis: tumour classification, ALT status, Ki-67 index, identification of
119	other mutations within tumour sample
120	The analyzed data, including methods and results of each full-length publication, were reviewed
121	to satisfy the selection criteria and assess the quality of the text. No studies were excluded as a
122	result of poor quality of methods or unsatisfactory results. Results were independently extracted
123	by one author (EW) and assessed by another independent author (FR) to ensure accuracy and
124	inclusion of complete data. Any discrepancies were resolved by discussion.
125	Synthesis of data

All relevant patient demographics and tumour data were collected and tabulated in 126 127 Excel[®]. Tumours that were referred to as ACTH-secreting tumours, ACTH-omas, or exhibited T-PIT expression were tabulated as corticotrophs. Null cell pituitary tumours were recorded as 128 129 nonfunctional pituitary adenomas. Similarly, gonadotrophs included tumours categorized by 130 LH/FSH secretion or SF1 expression. One study recorded gonadotrophs as nonfunctional pituitary 131 adenomas and did not specify the number of adenomas recorded [16]. Pit-1 lineage tumours 132 were further categorized into GH-secreting somatotroph and PRL-secreting lactotrophs. 133 Thyrotrophs included TSH-secreting adenomas and thyrotrophic adenomas. Any tumours that 134 did not fall under these categories were tabulated under "Other Tumour Type," including all plurihormonal tumours, pituitary carcinomas, and pituitary rhabdomyosarcoma. Tumours 135 136 exhibiting ATRX within the included categories were indicated within square brackets. Analytical 137 techniques and evaluation strategies were indicated in Table 1 while data that was unspecified 138 or not measured was recorded in Table 2. The statistical analysis included Fisher's exact test for 139 associations between tumour recurrence, and other tumour characteristics and ATRX loss. No 140 other statistical or sensitivity analyses were conducted.

141 Table 1. Characteristics of included publications examining the prevalence of ATRX loss in

142 human pituitary neuroendocrine tumours.

Author	Year	Journal	Country	Type of study	Sample size	Tumour Type	Evaluation Strategy	Loss o obsei (# if ne
Casar- Borota (Trouillas)	2017	The American Journal of Surgical Pathology	Denmark	Case report & descriptive cross- sectional study	248	152 clinically nonfunctioning pituitary adenomas, 2 pituitary carcinomas	Immunohistochemical analysis; NextGen Sequencing	Yes cortico pitu carcii

Guo (Wang)	2018	Frontiers in Oncology	China	Case report & literature review	1	Pituitary carcinoma	Immunohistochemical analysis; NextGen Sequencing	Ye
Chen (Dahiya)	2019	Journal of Neuropathy and Experimental Neurology	States of	Descriptive cross- sectional study	42	Pediatric pituitary adenoma	Immunohistochemical analysis	Ye: prolact
Sbiera (Fassnacht)	2019	Neuro- oncology	Germany	Descriptive cross- sectional study	18	Pituitary adenoma	Exome sequencing, Sanger sequencing	Ye: cortico
Heaphy (Rodriguez)	2020	Modern Pathology	United States of America	Descriptive cross- sectional study	106	Pituitary adenoma	Immunohistochemical analysis; Fluorescent in-situ telomere hybridization; Whole exome sequencing; NextGen Sequencing	Yes, 1 exhib loss of pro expre but mutat ATRX
Casar- Borota (Burman)	2021	The Journal of Clinical Endocrinology & Metabolism	Sweden	Descriptive cross- sectional study	47*	30 aggressive pituitary tumours, 17 pituitary carcinomas*	Immunohistochemical analysis; NextGen Sequencing	Yes, 8 c carcine cortico (2 carc 1, si carcine adeno lacto adeno lacto carcin
Lu (Chen)	2021	Frontiers in Endocrinology	United States of America	Case report	1	Pituitary rhabdomyosarcoma arising from pituitary adenoma	NextGen Sequencing	Ye
Alzoubi (Buttarelli)	2022	Endocrine Pathology	Italy	Descriptive cross- sectional study	36	•	Immunohistochemical analysis; Fluorescent in-situ telomere hybridization	Yes aggre ad recu

								cortico tum
Lamback (Gadelha)	2024	Journal of Clinical Endocrinology and Metabolism Case Reports	Brazil	Case report	1	Pituitary adenoma	Immunohistochemica analysis	Yes, 1 i pitu ader

- 143 ** One patient was omitted from the sample, as it was repeated from Casar-Borota et al. (2017)
- 144
- 145

146 **Table 2. Demographic and clinical patient data examined in the included publications.**

Author (Date)	Average Age	Sex	Recurrent Tumour	Non- recurrent Tumour	Clinically Non- functional	Corticotroph	Somatotrc
Casar- Borota (2017)	Unspecified [39]	Unspecified [F]	Unspecified	Unspecified	152	22	60
Guo (2018)	[55]	[M]	[1]	0	0	0	0
Chen (2019)	17.64 [unspecified]	27 F, 15 M [2 F, 1 M]	5	37 [3]	9	9	6
Sbiera (2019)	53.7 [52.5]	10 F, 8 M [2 F]	Unspecified	Unspecified	0	18	0

Heaphy (2020)	53.4 [unspecified]	41 M, 65 F [unspecified]	18 [unspecified]	88 [unspecified]	83	1	15
Casar- Borota (2021)*	45 [45]	14 F, 33 M [2F, 6M]	47 [8]	0	1	10 [3]	2
Lu (2021)	[77]	[M]	[1]	0	0	0	0
Alzoubi (2022)	Adult: 52.9 Pediatric: 13 [Adult: 60]	Adult: 12 F, 12 M Pediatric: 9 F, 3 M [1 M]	24 adults [1 adult]	12 pediatric	0	6 adults + 2 pediatric [1 adult]	1 adult
Lamback (2024)	63	[M]	[1]	0	[1]	0	0

147 Values in square brackets indicate samples with ATRX loss reported. ALT-positive = alternative-

148 lengthening of telomeres was present in the tumour sample

149 * One pituitary carcinoma was excluded as the patient was shared with Casar-Borota (2017)

150 ** Information regarding tumour type and status were incomplete and could not be determined

- 151 *** 4 pituitary carcinomas exhibited ATRX loss (2 corticotrophs, 1 silent corticotroph, 1 somato-
- 152 lactotroph)
- 153
- 154

155 **Potential for bias and risk of bias assessment**

156 Preliminary screening was accomplished by one of the authors (EW) and then reassessed

157 by a second author (FR) according to the defined criteria to ensure that the same data items were

- 158 collected. The information was extracted from the full text independently by each author. These
- 159 efforts were directed toward conducting the analysis with minimal bias. The study quality and
- 160 presence of biases were determined using the Joanna Briggs Institute (JBI) Critical Appraisal
- 161 Checklist for Studies Reporting Prevalence Data (see Table 3) and the JBI Critical Appraisal
- 162 Checklist For Case Reports (see Table 4) [15].

163 Table 3: Quality assessment using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist

164 for Prevalence Studies

	Casar- Borota (2017)	Chen (2019)	Sbiera (2019)	Heaphy (2020)	Casar- Borota (2021)	Alzoubi (2022)
Was the sample frame appropriate to address the target population?	Yes	Yes	Yes	Yes	Yes	Yes
Were study participants sampled in an appropriate way?	No	Yes	No	No	Yes	Yes
Was the sample size adequate?	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Were the study subjects and the setting described in detail?	No	Yes	Yes	No	Yes	Yes

Was the data analysis conducted with sufficient coverage of the identified sample?	Unclear	Yes	Yes	No	Yes	Yes
Were valid methods used for the identification of the condition?	Yes	Yes	Yes	Yes	Yes	Yes
Was the condition measured in a standard, reliable way?	Yes	Yes	Yes	Yes	Yes	Yes
Was there appropriate statistical analysis	No	Yes	Yes	Yes	No	Yes
Was the response rate adequate, and if not, was the low response rate managed appropriately?	N/A	N/A	N/A	N/A	N/A	N/A
Final Scores	3/8	7/8	6/8	4/8	6/8	7/8

165 N/A = Not applicable; the checklist item was not applicable to the study design

166 Studies with final scores ≥ 6 are reported as "great" quality. Studies with final scores ≤ 4 are

- 167 reported as "poor" quality. Studies with final scores = 5 are reported as "moderate" quality.
- 168

169

170 Table 4: The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Risk of Bias for Case

171 Reports that were identified

	Casar- Borota (2017)	Guo (2018)	Lu (2021)	Lamback (2024)
Were patient's demographic characteristics clearly described?	Yes	Yes	Yes	Yes
Was the patient's history clearly described and presented as a timeline?	Yes	Yes	Yes	Yes
Was the current clinical condition of the patient on presentation clearly described?	Yes	Yes	Yes	Yes

Were diagnostic tests or assessment methods and the results clearly described?	Yes	Yes	Yes	Yes
Was the intervention(s) or treatment procedure(s) clearly described?	Yes	Yes	Yes	Yes
Was the post-intervention clinical condition clearly described?	Yes	Yes	No	Yes
Were adverse events (harms) or	Unclear	Yes	Unclear	Yes
unanticipated events identified and described?				
•	Yes	Yes	Yes	Yes

172 Studies with final scores ≥ 6 are reported as "great" quality. Studies with final scores ≤ 4 are

173 reported as "poor" quality. Studies with final scores = 5 are reported as "moderate" quality.

174

175

176 **Results**

177 **Description of studies**

A total of 46 studies were identified from database search after duplicates were removed. Following screening of titles and abstracts, 16 irrelevant studies were excluded. All 30 of the remaining studies were retrieved and assessed for inclusion. Of these, 21 publications failed to meet our inclusion criteria and were subsequently excluded. Fourteen studies were excluded due to wrong patient population, of which eleven studies did not examine samples including PitNETs for ATRX expression and mutations, while three studies were excluded due to ATRX mutations occurring outside of the pituitary tumour. Additionally, seven studies were excluded due

incorrect study design, as the studies lacked inclusion of novel cases. Consequently, a total of
nine publications were included based on the predetermined criteria [16–24].

187 Quality assessments were conducted for the nine studies deemed eligible for inclusion in 188 our review study. Given that the selected descriptive cross-sectional studies were retrospective, 189 analyzing tissue samples and existing medical records, subject response rate was not applicable 190 and thus excluded from the risk of bias assessment. Accordingly, both case reports and 191 descriptive studies were evaluated using an 8-point scale across various checklist parameters 192 [15]. Of the nine human studies that analyzed the prevalence of ATRX loss in PitNETs, three 193 studies presented case reports of a novel case that exhibited ATRX loss, while five were 194 descriptive cross-sectional studies. One study presented both a novel case report and a 195 descriptive cross-sectional study and was evaluated under both quality assessments [16]. Of the 196 six descriptive studies included in the review, 4/6 (67%) studies received "great" scores (≥ 6), 197 while 2/6 (33%) studies were categorized as "poor" quality (<4) [16,20]. All four case reports 198 received "great" scores (see Tables 1 and 2).

199 Table 3 summarizes the characteristics of the studies examined, including demographic 200 data, sample size, and evaluation strategies. All studies examined were published since 2017. A 201 study was published in each of Canada, China, Denmark, Germany, Italy, Sweden, and Brazil, and 202 three studies published in the USA. Eight studies conducted immunohistochemical analysis to 203 determine ATRX protein presence, while four studies conducted NextGen sequencing to 204 determine the presence and location of ATRX gene mutations. One study did not conduct either 205 immunohistochemical analysis or NextGen sequencing. Instead, the study examined selected 206 tumours using whole-exome sequencing and Sanger sequencing [19].

207 As 7/9 (78%) of the studies were conducted on data collected prior to the change in 208 pituitary tumour classification, the tumours were referred to as pituitary adenomas. Four studies 209 examined adult pituitary tumour patients [17,19,22,24], while one study examined pediatric 210 pituitary adenoma patients [18]. Three studies included both adult and pediatric pituitary 211 adenoma patients [20,21,23]. One study did not disclose the age range of the patients included 212 in their study [16]. In total, 20 pituitary carcinoma patients were also included from three studies 213 in addition to their pituitary adenoma patients [16,17,21]. Additionally, one study presented a 214 novel case study regarding a pituitary rhabdomyosarcoma arising from a pituitary adenoma that 215 was identified to have a mutation in ATRX [22].

216 Patient data from the studies were summarized in Table 4, including basic patient 217 information and tumour types. A total of 500 tumours were examined across the nine studies 218 included. 246 tumours were clinically non-functional adenomas, 84 somatotroph adenomas, 68 219 corticotroph adenomas, 50 lactotroph adenomas, 13 gonadotroph adenomas, 2 thyrotroph 220 adenomas, and 6 pituitary adenomas present with Pit-1. Several plurihormonal tumours were 221 also included and were described in Table 4. The studies also reported 20 pituitary carcinomas, 222 including 14 classified as corticotroph, 3 as lactotroph, 2 as somatotroph, and 1 as plurihormonal. 223 It was noted that in 3 of the studies reviewed, data involving age (average), sex, and tumour 224 recurrence was incomplete [16,19,20]. Of the reported ages, the weighted average age of 225 patients was 44. Among the publications that included sex distribution data, there were 138 226 female patients and 115 male patients. Additionally, 97 tumors were identified as recurrent, 227 while 138 were classified as non-recurrent.

228	Histopathological data regarding all tumours exhibiting ATRX loss included in this review
229	were summarized in Table 5. Only 19/500 (3.8%) tumours exhibited ATRX loss, of which 11/19
230	(58%) tumours were classified as corticotrophs while 4/19 (21%) lactotrophs. One study reported
231	a loss of ATRX protein expression in one tumour and partial loss in four other tumours, but did
232	not describe the patient or tumour type of the tumours that exhibited loss of ATRX protein
233	expression [20]. Furthermore, the researchers sequenced only the tumour sample that exhibited
234	full loss of ATRX expression and did not reveal any ATRX genetic abnormalities. They also did not
235	evaluate further the four cases that showed partial loss, and no information was provided
236	regarding the extent of the loss, so they were not classified as ATRX-negative tumors. 16/19 (84%)
237	of the tumours lacking ATRX expression were collected from adult patients, with the remaining
238	three reported as pediatric cases [18].

	Source	Tumour Classification	Age	Sex	Evaluatio n	Recurrenc e Status	ALT Statu s	Ki67	Mutations Ident
Tumou	Casar- Borota	Corticotroph							
r 1	(2017)	pituitary carcinoma	39	F	IHC, NGS	NA	NA	NA	c.134_5217del; p.D45-K
Tumou r 2		Corticotroph pituitary carcinoma	55	М	IHC, NGS	+	NA	80%	unspecified ATRX mutat
Tumou r 3**	Chen (2019)	Lactotroph	NA	F	IHC	_	NA	<3%	NA
Tumou r 4**	Chen (2019)	Lactotroph	NA	F	IHC	-	NA	<3%	NA
Tumou r 5**	Chen (2019)	Lactotroph	NA	м	IHC	_	NA	>3%	NA
Tumou r 6		Corticotroph	56	F	WES	NA	NA	1-2%	c.622G>C; p.Asp208His
Tumou r 7		Corticotroph	40	F	WES	NA	NA	5-6%	g.7577127C>A; p.Glu27

239	Table E. Domographic and historiathological characteristics of tumours exhibiting ATRY
239	Table 5. Demographic and histopathological characteristics of tumours exhibiting ATRX.

	Heaphy (2020)	NA	NA		IHC, WES, FISH		+	NA	no mutations in ATRX g
Tumou		Corticotroph pituitary carcinoma	45***	М	IHC, NGS	+	NA	NA	c.748C>T; p.Arg250Ter
Tumou r 10		Corticotroph pituitary carcinoma	45***	М	IHC, NGS	+	NA	NA	c.6679delG; p.Asp2227 c.3583delA; p.Arg1195f
Tumou		Corticotroph pituitary carcinoma	45***	F	IHC, NGS	+	NA		c.4048_4049delGG;
Tumou r 12		Somato-lactotroph carcinoma	45***	М	IHC, NGS	+	NA	NA	c.595_6669del, p.N199
Tumou		Corticotroph	45***	M	IHC, NGS	+	NA	NA	c.2422C>T, p.Arg808Te
Tumou		Corticotroph	45***	М	IHC, NGS	+	NA	NA	c.839_840insCATG, p.A
Tumou	Casar- Borota	Silent corticotroph	45***		IHC, NGS		NA	NA	 c.5938T>A,c.5939delC, p.Ser1980fs
Tumou	Casar- Borota		45***		IHC, NGS			NA	c.21_6699del, p.E8-K22
Tumou		Pituitary rhabdomyosarcom a arising from pituitary adenoma	77		NGS	+			
Tumou	Alzoubi	. ,			IHC, FISH				NA
Tumou		Nonfunctional null- cell pituitary						11%	
-		_							

240 NA = Statistic was not reported or not made available, + = Status associated with column was

243 hybridization, WES = whole exome sequencing

²⁴¹ present, - = Status was evaluated but not present at the time of reporting, IHC =

immunohistochemical analysis, NGS = NextGen sequencing, FISH = fluorescent in-situ

- * Mutation was collected from Casar-Borota et al. (2021)
- ** The three lactotrophs in Chen (2019) reported to lack ATRX expression did not specify which
 of the three cases exhibited a Ki67 index > 3%.

247 *** Only average age was reported for the 8 tumours reported to lack ATRX expression. Range

- 248 of ages was reported as 23-72
- 249
- 250

251 Two studies [20,22] reported the number of patients exhibiting the ALT phenotype, of 252 which a total of 14 cases were identified and only 2/14 (14%) tumours exhibited ATRX loss. 5/9 253 studies reported the presence of other mutations within ATRX-negative tumours, of which TP53 254 was the most frequently reported mutation (10/18). One study investigated the presence of 20 common glioma mutations, including IDH1, IDH2, and ATRX, within the analyzed pituitary 255 256 tumours, of which 1/248 tumours exhibited a loss of ATRX due to a large deletion within the gene 257 [16]. It was not specified, however, what the other 17 mutations the tumour was screened for or 258 if any other mutations were observed. Ki-67 index was also reported by five studies [17–19,23,24] 259 with different parameters, in which two studies reported proliferation indices greater than 3% as 260 elevated [18,19], whereas another study reported indices greater than 2% as elevated [23]. One study reported an increase in their Ki-67 index by 80% from a prior examination but did not 261 262 disclose what the absolute values were [17]. One study also reported indices greater than 10% 263 as a marker of high proliferation but did not specify what they determined to be the threshold 264 for an elevated index [24]. One study investigated aggressive pituitary adenomas and pituitary 265 carcinomas, which were both characterized by increased proliferation [21].

266 Of the 20 pituitary carcinomas included in the review, 6/20 (30%) exhibited a loss of ATRX 267 expression. 5/6 (83%) carcinomas with ATRX loss were corticotroph in nature while 1/6 (17%) 268 presented as a somato-lactotroph. The remaining 14 pituitary carcinomas shared a similar 269 distribution, with 9/14 (64%) of the carcinomas reported to be corticotroph in nature, 3/14 (21%) 270 as lactotroph in nature, and 2/14 (14%) as somatotroph in nature. The average age of pituitary 271 carcinoma patients was between 16 and 69, with an average age of 42.5. Unfortunately, average 272 age of carcinomas exhibiting ATRX loss cannot be calculated due to incomplete reporting by one 273 study [21]. All carcinomas exhibited aggressive and transformative properties concomitant with 274 their diagnosis, including elevated proliferative growth, need for repeated surgical procedures, 275 resistance to drug therapies, and development of metastases. None of the studies that included 276 pituitary carcinomas examined the presence of the ALT phenotype. Only one study [17] 277 measured Ki-67 and reported an increase by 80% from a previous examination but did not 278 provide information regarding the absolute value itself.

279 In the analysis of the relationship between ATRX loss and tumour recurrence [Table 6A], 280 tumour hormone secretion [Table 6B], and patient sex [Table 6C], one study was excluded due 281 to incomplete data regarding tumour recurrence, tumour type, and sex of patients with ATRX 282 loss [20]. Two other studies were excluded from tumour recurrence and sex analysis due to 283 incomplete reporting on the two parameters [16,19]. We did not find any significant relationship 284 between loss of ATRX expression and tumour recurrence status [Table 6A]. Sex was also not a 285 significant factor in ATRX expression [Table 6C]. However, tumour type was associated with ATRX expression status. As described in Table 6B, the proportion of ACTH-secreting tumours 286 287 (corticotroph adenomas and corticotrophic pituitary carcinomas) exhibiting loss of ATRX

- 288 expression was significantly different from the proportion of other tumours that exhibited ATRX
- loss (p < 0.0005). No other significant associations were observed.
- 290 Table 6. Fisher's exact tests comparing ATRX expression status and tumour recurrence (A),
- 291 tumour hormone secretion type (B), and sex of patient (C).

A	Status of AT			
Tumour Recurrence**	ATRX Loss	ATRX Intact	Total	p-value
Recurrent	12	67	79	0.071
Non-recurrent	3	46	49	
Total	15	113	128	
В	Status of AT			
Tumour Hormone Secretion***	ATRX Loss	ATRX Intact	Total	p-value
ACTH	11	72	83	1.49E-04*
Other	7	305	312	
Total	18	376	395	
С	Status of AT			
Sex****	ATRX Loss	ATRX Intact	Total	p-value
Male	10	63	73	0.152
Female	7	66	73	
Total	17	129	146	

* Indicates significant p-value (*p* < 0.05)

293 ** Casar-Borota et al. (2017), Sbiera et al. (2019), and Heaphy et al. (2020) were excluded due

294 to incomplete data reporting regarding tumour recurrence status

295 *** Heaphy et al. (2020) was excluded due to incomplete data reporting regarding tumour

type. The nonfunctional case presented by Lamback et al. (2024) was included under "Other".

297 **** Casar-Borota et al. (2017) and Heaphy et al. (2020) were excluded due to incomplete data

298 reporting regarding patient sex

300

301 **Discussion**

In the current study, we reviewed all available literature on ATRX expression in PitNETs. Our analysis revealed a loss of ATRX expression in approximately 3.8% of the 500 cases that were studied. Although ATRX is rarely mutated within PitNETs, patients with functioning PitNETs, especially corticotrophs, are over-represented (p < 0.0005).

We observed ATRX loss in 4 PitNETs exhibiting the ALT phenotype. However, not all ALTpositive tumours exhibited ATRX loss, suggesting that ATRX loss is not required for the ALT phenotype to progress within the PitNETs studied. While ATRX loss has been strongly associated with the ALT phenotype tumour types such as gliomas and pancreatic tumours, we cannot determine a relationship between ATRX function and the progression of the ALT phenotype in PitNETs from currently published data.

312 Given ATRX's critical role in sustaining methylation of repetitive DNA regions, a loss of ATRX expression may lead to errors in DNA replication and transcription during cell division. 313 314 Coupled with an increased propensity for the development of the ALT phenotype, impaired ATRX 315 function may promote the aberrant proliferative and transformative qualities observed in the 316 analysis. Similar trends have also been identified in Pancreatic NETs, where the loss of 317 ATRX/DAXX expression is associated with an increased propensity for proliferative development 318 and poor survival [6]. All studies reviewed herein reported an increase in proliferative or 319 transformative properties in tumours lacking ATRX expression. Four studies reported an elevated

incidence of ATRX loss in recurrent or aggressive PitNETs, both of which presented with elevated
 proliferative traits [20,21,23,24]. However, given the multitude of factors, including initial degree
 of tumour resection and tumour location, the data we collected and analyzed from the
 publications demonstrated a non-significant trend with ATRX loss and recurrence in PitNETs.

324 Loss of ATRX expression was also noted in 30% of the 20 pituitary carcinomas presented 325 across the studies included in this review. Pituitary carcinomas exhibit significant proliferative 326 and transformative properties. The elevated prevalence of ATRX mutations among pituitary 327 carcinomas supports the proposed association between ATRX loss and increased propensity for 328 aggressive and proliferative development of tumours. It was also identified that 83% of the ATRX-329 negative carcinomas were corticotroph in nature, similar to the trends identified in the data from 330 other ATRX-negative pituitary tumours collected in the review. However, as corticotrophic 331 carcinomas were overrepresented across the samples, making up 70% of all reported pituitary 332 carcinomas, it is difficult to draw any conclusions from this observation. It is also important to 333 note that in one excluded study, a pituitary carcinoma was found to exhibit ATRX mutations and 334 expression loss in a liver metastasis but not in the original tumour, highlighting the potential for 335 pituitary carcinomas to gain ATRX mutations [25].

336 It is worth noting that mutations in TP53, a well-established oncogene, were identified in 337 53% of tumours lacking ATRX expression in this study. As one of the most frequently mutated 338 genes in cancer, TP53 mutants are strongly associated with proliferative development [26]. The 339 concomitant presence of TP53 and ATRX mutations complicates the selective examination of 340 ATRX loss on the development and prognosis of PitNETs. Given the role of p53 in DNA repair and

tumour suppression, TP53 alterations may increase the propensity for ATRX mutations, thereby promoting proliferative development in pituitary tumours. Future studies may consider investigating ATRX expression in PitNETs and the interplay with TP53 mutations in prognosis of these patients.

345 All tumours exhibiting ATRX mutations and loss discussed in this review were identified 346 using either immunohistochemical analysis (IHC), next-generation sequencing (NGS), or a 347 combination of both. The use of IHC for pathological analysis is a standard practice for endocrine 348 and neurological tumour diagnoses as a relatively inexpensive means of detecting changes in 349 protein expression. As ATRX mutations commonly result in truncated proteins, IHC is used to 350 identify loss of ATRX protein expression common in several tumour types [27,28]. However, 351 certain ATRX mutations have been found to result in false ATRX positivity during IHC due to 352 positive staining for protein expression despite loss in protein function [29]. As IHC is limited by 353 the antibodies available for detection, unusual mutations can limit the accuracy and effectiveness 354 of such analyses for ATRX mutations. Furthermore, there is also a lack of standardization 355 regarding determination of ATRX loss in tumours like gliomas, where specific thresholds for 356 positive ATRX expression detected by IHC are not well enforced and vary between studies [30]. 357 NGS allows for more comprehensive detection of tumour mutations and can detect multiple 358 mutations across many genes in a single analysis. However, NGS is more costly and time 359 intensive, making it less accessible [31]. NGS may also miss mutations outside of the gene that 360 are impairing ATRX expression. Heaphy et al. identified a loss of ATRX expression in one case by 361 IHC but did not identify any mutations from NGS, suggesting an external mechanism affecting

362 ATRX expression [20]. A combination of IHC and NGS should be applied to provide comprehensive363 tumour examination.

Three studies also used a combination of IHC, fluorescence in-situ hybridization (FISH), and whole exome sequencing (WES for detection of ATRX mutations [19,20,23]. While FISH offers a cost-effective means of detecting large mutations, it is not sensitive enough to detect small intergenic changes that may affect ATRX expression [31]. WES applies similar practices to NGS, but instead examines a sample's entire exome sequence, leading to far higher costs and time detection [29]. Thus, both FISH and WES are not as effective for frequent detection of ATRX mutations in PitNETs.

371 Limitations

372 The aim of this study was to review all published research on ATRX mutation and 373 expression in pituitary neuroendocrine tumours. To do so we must accept that we are limited to 374 the type and quality of the published articles from other leading researchers within the field. 375 With regards to our study, we found that the main limitation we identified was the heterogeneity 376 in reporting of results, hampering the ability to perform analyses regarding outcome. For 377 example, one study [20] did not report the tumour type or demographic data of the tumours 378 exhibiting ATRX expression loss, while two other studies [16,19] did not report the average age, 379 sex, and tumour recurrence status of patients in the study. Information regarding duration of 380 follow-up following prognosis and treatment were also incomplete across the study reported in 381 this review. Five studies reported varying follow-up periods between 6 months to 24 years, with 382 many limited by patient loss and time between evaluation and publication [17,18,21,22,24]. Two 383 studies also reported on the recurrent tumour characteristics and did not describe any

evaluations of ATRX expression in the initial tumour [20,23]. Two studies did not present follow-384 385 up reports and data of the pituitary tumours [16,19]. The limited data presented regarding past 386 visits and follow-up periods for patients included in each study hinders investigations on links to 387 aggressive behaviour and recurrence. As a diagnostic marker of aggressive behaviour is 388 recurrence, limited reporting and length of follow-up results may be omitting potential tumours 389 exhibiting ATRX loss. Measurement variability also limited investigations, as the included studies 390 used different parameter thresholds for evaluation. The lack of a standard for declaring ATRX loss 391 and the limited reporting on thresholds used during IHC affect the validity of IHC evaluations of 392 ATRX loss. Furthermore, reporting on proliferative markers like Ki67 were inconsistent, with 393 varied standards for elevated values. As mentioned earlier, two studies reported elevated Ki67 394 as values greater than 3% [18,19], while one study reported values greater than 2% as being 395 elevated [23]. The inconsistent reporting of measurements limited any analyses and 396 investigations. Additionally, the limited research available regarding ATRX expression loss in 397 pituitary tumours further restricted the statistical power of the review, as very few centres were 398 involved in the collection of pituitary tumour samples used in the eight studies examined in the 399 review. As most patients were collected from neurosurgical centres, patient data may be biased 400 towards more severe and aggressive tumour cases.

401 **Future research**

402 Our literature search revealed that all identified studies were published since 2017, 403 highlighting this as an emerging field that requires further investigation. By comparing larger 404 cohorts of PitNETs with ATRX loss to those with intact ATRX function, along with adequate long-

405 term follow-up on outcomes, we can better understand the clinical significance of ATRX loss in406 PitNETs.

407

408 **Conclusions**

Both ATRX loss and mutations are uncommon in PitNETs but when they do occur, they 409 primarily affect functional tumours, particularly those of the ACTH lineage. Furthermore, 410 411 tumours lacking ATRX expression exhibit increased proliferative or transformative 412 characteristics, including a higher incidence of ATRX loss in pituitary carcinomas. While previous 413 research has shown that ATRX represses the activation of the ALT phenotype, we identified the 414 ALT phenotype in some tumours with ATRX loss. However, not all tumours exhibiting the ALT 415 phenotype showed ATRX loss, suggesting a more complex relationship between ATRX expression 416 and ALT phenotype activation in PitNETs. This is an emerging area of study, and larger, 417 prospective studies with long follow-up and consistent reporting are crucial to further investigate 418 the implications of ATRX expression loss in PitNETs.

419

420 Acknowledgment

421 Authors are grateful to the Lloyd Carr-Harris Foundation for their continuous support.

422

423 **References**

Xue Y, Gibbons R, Yan Z, Yang D, McDowell TL, Sechi S, et al. The ATRX syndrome protein
 forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic

- 426 leukemia nuclear bodies. Proceedings of the National Academy of Sciences. 2003;100:
- 427 10635–10640. doi:10.1073/pnas.1937626100
- 428 2. Voon HPJ, Wong LH. New players in heterochromatin silencing: histone variant H3.3 and
- 429 the ATRX/DAXX chaperone. Nucleic Acids Res. 2016;44: 1496–1501.
- 430 doi:10.1093/nar/gkw012
- 431 3. Iwase S, Xiang B, Ghosh S, Ren T, Lewis PW, Cochrane JC, et al. ATRX ADD domain links an
- 432 atypical histone methylation recognition mechanism to human mental-retardation
- 433 syndrome. Nat Struct Mol Biol. 2011;18: 769–76. doi:10.1038/nsmb.2062
- 434 4. Eustermann S, Yang J-C, Law MJ, Amos R, Chapman LM, Jelinska C, et al. Combinatorial
- 435 readout of histone H3 modifications specifies localization of ATRX to heterochromatin.

436 Nat Struct Mol Biol. 2011;18: 777–782. doi:10.1038/nsmb.2070

- 437 5. Darmusey L, Pérot G, Thébault N, Le Guellec S, Desplat N, Gaston L, et al. ATRX Alteration
- 438 Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas. Cancers
- 439 (Basel). 2021;13: 2151. doi:10.3390/cancers13092151
- 440 6. Singhi AD, Liu T-C, Roncaioli JL, Cao D, Zeh HJ, Zureikat AH, et al. Alternative Lengthening
- 441 of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor
- 442 Survival in Patients with Pancreatic Neuroendocrine Tumors. Clinical Cancer Research.
- 443 2017;23: 600–609. doi:10.1158/1078-0432.CCR-16-1113
- 444 7. Nandakumar P, Mansouri A, Das S. The Role of ATRX in Glioma Biology. Front Oncol.
- 445 2017;7. doi:10.3389/fonc.2017.00236
- 446 8. Ren X, Tu C, Tang Z, Ma R, Li Z. Alternative lengthening of telomeres phenotype and loss
- 447 of ATRX expression in sarcomas (Review). Oncol Lett. 2018. doi:10.3892/ol.2018.8318

- 448 9. Xie Y, Wang H, Wang S, Feng Y, Feng Y, Fan S, et al. Clinicopathological Significance of
- 449 ATRX Expression in Nasopharyngeal Carcinoma Patients: A Retrospective Study. J Cancer.
- 450 2021;12: 6931–6936. doi:10.7150/jca.63333
- 451 10. Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO Classification of
- 452 Pituitary Tumors. Endocr Pathol. 2022;33: 6–26. doi:10.1007/s12022-022-09703-7
- 453 11. Russ S, Anastasopoulou C, Shafiq I. Pituitary Adenoma. StatPearls; 2024.
- 454 12. Nishioka H. Aggressive pituitary tumors (PitNETs). Endocr J. 2023;70: EJ23-0007.
- 455 doi:10.1507/endocrj.EJ23-0007
- 456 13. Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European
- 457 Society of Endocrinology Clinical Practice Guidelines for the management of aggressive
- 458 pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178: G1–G24. doi:10.1530/EJE-
- 459 17-0796
- 460 14. Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, et al. Aggressive
- 461 pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol. 2021;17: 671–684.
- 462 doi:10.1038/s41574-021-00550-w
- 463 15. Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z. JBI Manual for Evidence Synthesis.

464 Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, editors. JBI; 2024.

- 465 doi:10.46658/JBIMES-24-01
- 466 16. Casar-Borota O, Botling J, Granberg D, Stigare J, Wikström J, Boldt HB, et al. Serotonin,
- 467 ATRX, and DAXX Expression in Pituitary Adenomas: Markers in the Differential Diagnosis
- 468 of Neuroendocrine Tumors of the Sellar Region. Am J Surg Pathol. 2017;41: 1238–1246.
- 469 doi:10.1097/PAS.000000000000908

- 470 17. Guo F, Wang G, Wang F, Xu D, Liu X. Identification of Novel Genes Involved in the
- 471 Pathogenesis of an ACTH-Secreting Pituitary Carcinoma: A Case Report and Literature
- 472 Review. Front Oncol. 2018;8: 510. doi:10.3389/fonc.2018.00510
- 473 18. Chen J, Schmidt RE, Dahiya S. Pituitary Adenoma in Pediatric and Adolescent Populations.
- 474 J Neuropathol Exp Neurol. 2019;78: 626–632. doi:10.1093/jnen/nlz040
- 475 19. Sbiera S, Perez-Rivas LG, Taranets L, Weigand I, Flitsch J, Graf E, et al. Driver mutations in
- 476 USP8 wild-type Cushing's disease. Neuro Oncol. 2019;21: 1273–1283.
- 477 doi:10.1093/neuonc/noz109
- 478 20. Heaphy CM, Bi WL, Coy S, Davis C, Gallia GL, Santagata S, et al. Telomere length
- 479 alterations and ATRX/DAXX loss in pituitary adenomas. Mod Pathol. 2020;33: 1475–1481.
- 480 doi:10.1038/s41379-020-0523-2
- 481 21. Casar-Borota O, Boldt HB, Engström BE, Andersen MS, Baussart B, Bengtsson D, et al.
- 482 Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX
- 483 Mutations. J Clin Endocrinol Metab. 2021;106: 1183–1194. doi:10.1210/clinem/dgaa749
- 484 22. Lu J, Chen L. Molecular Profile of a Pituitary Rhabdomyosarcoma Arising From a Pituitary
- 485 Macroadenoma: A Case Report. Front Endocrinol (Lausanne). 2021;12: 752361.
- 486 doi:10.3389/fendo.2021.752361
- 487 23. Alzoubi H, Minasi S, Gianno F, Antonelli M, Belardinilli F, Giangaspero F, et al. Alternative
- 488 Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter
- 489 Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.
- 490 Endocr Pathol. 2022;33: 494–505. doi:10.1007/s12022-021-09702-0

- 491 24. Lamback E, Miranda RL, Ventura N, Chimelli L, Gadelha MR. Loss of ATRX Protein
- 492 Expression in an Aggressive Null Cell Pituitary Tumor. JCEM Case Reports. 2024;2.
- 493 doi:10.1210/jcemcr/luae143
- 494 25. Sumislawski P, Rotermund R, Klose S, Lautenbach A, Wefers AK, Soltwedel C, et al. ACTH-
- 495 secreting pituitary carcinoma with TP53, NF1, ATRX and PTEN mutations Case report and
- 496 review of the literature. Endocrine. 2022;76: 228–236. doi:10.1007/s12020-021-02954-0
- 497 26. Olivier M, Hollstein M, Hainaut P. TP53 Mutations in Human Cancers: Origins,
- 498 Consequences, and Clinical Use. Cold Spring Harb Perspect Biol. 2010;2: a001008–
- 499 a001008. doi:10.1101/cshperspect.a001008
- 500 27. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, et al. Altered Telomeres in
- 501 Tumors with *ATRX* and *DAXX* Mutations. Science (1979). 2011;333: 425–425.
- 502 doi:10.1126/science.1207313
- 503 28. Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, et al.
- 504 ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH
- 505 mutant astrocytic tumors with better prognosis. Acta Neuropathol. 2013;126: 443–451.
- 506 doi:10.1007/s00401-013-1156-z
- 507 29. Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, et al. ATRX and IDH1-
- 508 R132H immunohistochemistry with subsequent copy number analysis and IDH
- 509 sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma,
- 510 oligodendroglioma and glioblastoma. Acta Neuropathol. 2015;129: 133–146.
- 511 doi:10.1007/s00401-014-1370-3

- 512 30. Tanboon J, Williams EA, Louis DN. The Diagnostic Use of Immunohistochemical
- 513 Surrogates for Signature Molecular Genetic Alterations in Gliomas. J Neuropathol Exp
- 514 Neurol. 2016;75: 4–18. doi:10.1093/jnen/nlv009
- 515 31. Scheie D, Kufaishi HHA, Broholm H, Lund EL, de Stricker K, Melchior LC, et al. Biomarkers
- 516 in tumors of the central nervous system a review. APMIS. 2019;127: 265–287.
- 517 doi:10.1111/apm.12916
- 518

519 Supporting Information

520 Figure S1. PRISMA 2020 Checklist





